{"title":"Cardiovascular Dysfunction in Type 2 Diabetes: The Role of MicroRNAs.","authors":"Gizem Kayki-Mutlu, Ebru Arioglu-Inan","doi":"10.1007/164_2026_799","DOIUrl":null,"url":null,"abstract":"<p><p>Type 2 diabetes (T2D) is a major health concern that leads to multiple chronic complications. Among these, cardiovascular dysfunction is a prominent contributor to the morbidity and mortality associated with T2D. MicroRNAs (miRNAs) are non-coding RNAs that regulate protein synthesis by activating or suppressing target genes. Recently, their role in the cardiovascular complications of T2D has attracted significant attention. Several miRNAs have emerged as key regulators. In diabetic hearts, miRNAs such as miR-133, miR-1, miR-34a, and miR-21 influence critical processes, including hypertrophy, fibrosis, oxidative stress, and cell death. miR-126, in particular, is one of the most studied miRNAs in the context of vascular function in T2D, playing a crucial role in endothelial function, vascular integrity, and angiogenesis. Evidence to date suggests that altered levels of specific miRNAs contribute to cardiovascular dysfunction in T2D, making them potential therapeutic targets for preventing or treating these complications. In this chapter, we aim to discuss the impact of miRNAs on the cardiovascular system in T2D.</p>","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"165-195"},"PeriodicalIF":0.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Handbook of experimental pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/164_2026_799","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Type 2 diabetes (T2D) is a major health concern that leads to multiple chronic complications. Among these, cardiovascular dysfunction is a prominent contributor to the morbidity and mortality associated with T2D. MicroRNAs (miRNAs) are non-coding RNAs that regulate protein synthesis by activating or suppressing target genes. Recently, their role in the cardiovascular complications of T2D has attracted significant attention. Several miRNAs have emerged as key regulators. In diabetic hearts, miRNAs such as miR-133, miR-1, miR-34a, and miR-21 influence critical processes, including hypertrophy, fibrosis, oxidative stress, and cell death. miR-126, in particular, is one of the most studied miRNAs in the context of vascular function in T2D, playing a crucial role in endothelial function, vascular integrity, and angiogenesis. Evidence to date suggests that altered levels of specific miRNAs contribute to cardiovascular dysfunction in T2D, making them potential therapeutic targets for preventing or treating these complications. In this chapter, we aim to discuss the impact of miRNAs on the cardiovascular system in T2D.
期刊介绍:
The Handbook of Experimental Pharmacology is one of the most authoritative and influential book series in pharmacology. It provides critical and comprehensive discussions of the most significant areas of pharmacological research, written by leading international authorities. Each volume in the series represents the most informative and contemporary account of its subject available, making it an unrivalled reference source.